Latest & greatest articles for Hypertrichosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Hypertrichosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Hypertrichosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Hypertrichosis

1. Assessment of hirsutism

Assessment of hirsutism Assessment of hirsutism - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of hirsutism Last reviewed: February 2019 Last updated: November 2018 Summary Hirsutism is a condition seen in women that is associated with development of androgen-dependent terminal hair (coarse, pigmented) following a male-pattern distribution (face, chest, abdomen, back). Pathophysiology Hair in different (...) =bestpractice.com Hair response to androgens varies from person to person and includes increase in follicle size, fibre diameter, and the amount of time spent in anagen (the growth-cycle phase). Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005 Dec 15;353(24):2578-88. http://www.ncbi.nlm.nih.gov/pubmed/16354894?tool=bestpractice.com Messenger AG. The control of hair growth: an overview. J Invest Dermatol. 1993 Jul;101(suppl 1):4S-9S. http://www.ncbi.nlm.nih.gov/pubmed/8326154?tool=bestpractice.com

2018 BMJ Best Practice

2. Evaluation and Treatment of Hirsutism in Premenopausal Women Full Text available with Trip Pro

is present ( ). Hirsutism must be distinguished from hypertrichosis—generalized excessive hair growth that may be hereditary or result from certain medications ( e.g. , phenytoin, cyclosporine). Hypertrichosis is distributed in a generalized, nonsexual pattern ( i.e. , predominantly on forearms or lower legs) and is not caused by excess androgen (although hyperandrogenemia may aggravate it). Pathogenesis of hirsutism The growth of sexual hair is entirely dependent on the presence of androgen (...) Evaluation and Treatment of Hirsutism in Premenopausal Women We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term

2018 The Endocrine Society

3. Evaluation and Treatment of Hirsutism in Premenopausal Women Full Text available with Trip Pro

Evaluation and Treatment of Hirsutism in Premenopausal Women 29522641 2018 07 03 2019 01 18 1538-3598 319 15 2018 Apr 17 JAMA JAMA Evaluation and Treatment of Hirsutism in Premenopausal Women. 1613-1614 10.1001/jama.2018.2611 Mimoto Mizuho S MS University of Chicago, Chicago, Illinois. Oyler Julie L JL University of Chicago, Chicago, Illinois. Davis Andrew M AM University of Chicago, Chicago, Illinois. eng P30 DK020595 DK NIDDK NIH HHS United States T32 DK007011 DK NIDDK NIH HHS United States (...) Journal Article United States JAMA 7501160 0098-7484 0 Androgen Antagonists 0 Contraceptives, Oral, Hormonal 3XMK78S47O Testosterone 68-96-2 17-alpha-Hydroxyprogesterone AIM IM 17-alpha-Hydroxyprogesterone blood Adult Androgen Antagonists therapeutic use Contraceptives, Oral, Hormonal therapeutic use Female Hair Removal Hirsutism diagnosis drug therapy therapy Humans Polycystic Ovary Syndrome Practice Guidelines as Topic Premenopause Testosterone blood 2018 3 10 6 0 2018 7 4 6 0 2018 3 10 6 0 ppublish

2018 JAMA

4. Assessment of hirsutism

Assessment of hirsutism Assessment of hirsutism - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of hirsutism Last reviewed: February 2019 Last updated: November 2018 Summary Hirsutism is a condition seen in women that is associated with development of androgen-dependent terminal hair (coarse, pigmented) following a male-pattern distribution (face, chest, abdomen, back). Pathophysiology Hair in different (...) =bestpractice.com Hair response to androgens varies from person to person and includes increase in follicle size, fibre diameter, and the amount of time spent in anagen (the growth-cycle phase). Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005 Dec 15;353(24):2578-88. http://www.ncbi.nlm.nih.gov/pubmed/16354894?tool=bestpractice.com Messenger AG. The control of hair growth: an overview. J Invest Dermatol. 1993 Jul;101(suppl 1):4S-9S. http://www.ncbi.nlm.nih.gov/pubmed/8326154?tool=bestpractice.com

2018 BMJ Best Practice

5. Association of ethnicity, Fitzpatrick skin type, and hirsutism: A retrospective cross-sectional study of women with polycystic ovarian syndrome Full Text available with Trip Pro

Association of ethnicity, Fitzpatrick skin type, and hirsutism: A retrospective cross-sectional study of women with polycystic ovarian syndrome The complex interplay between ethnicity, Fitzpatrick skin type (FST), and hirsutism in patients with polycystic ovarian syndrome (PCOS) is poorly understood.In this cross-sectional, retrospective analysis, we examined the prevalence, severity, and distribution of hirsutism with clinician-rated site-specific and total modified Ferriman-Gallwey (mFG (...) ) visual scoring in a diverse cohort of American patients with PCOS.Independent analyses were conducted on the basis of patient-reported FST ratings and ethnicity.In this PCOS cohort, a correlation was found between hirsutism and ethnicity and the highest prevalence of hirsutism and total mFG scores was observed in Hispanic, Middle Eastern, African American, and South Asian patients. A positive correlation between hirsutism and FST was also observed with an increasing prevalence of hirsutism

2017 International journal of women's dermatology

6. Endocrine evaluation of hirsutism Full Text available with Trip Pro

Endocrine evaluation of hirsutism Hirsutism is defined as excessive terminal hair growth in a male pattern in females. It typically affects 5 to 10% of reproductive-age women. Excessive hair growth can often cause significant psychological and emotional distress. As a result, hirsutism is a common presenting complaint to healthcare professionals, including dermatologists, as women search for cosmetic and medical solutions to their problem. Hirsutism results from excess production of androgens (...) , often from ovarian or adrenal sources. It is typically associated with a metabolic syndrome like polycystic ovarian syndrome (PCOS), but can be idiopathic or medication-induced. This article provides an endocrine perspective for the evaluation and management of hirsutism.

2017 International journal of women's dermatology

7. Hirsutism: Evaluation and Treatment

Hirsutism: Evaluation and Treatment No. 350-Hirsutism: Evaluation and Treatment - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 39, Issue 11, Pages 1054–1068 No. 350-Hirsutism: Evaluation and Treatment x Kimberly Liu Correspondence Corresponding Author: Dr. Kimberly Liu; University of Toronto, Department of Obstetrics and Gynecology, Toronto ON , MD ∗ , x Kimberly Liu Correspondence Corresponding Author: Dr. Kimberly (...) Liu; University of Toronto, Department of Obstetrics and Gynecology, Toronto ON Toronto, ON x Tarek Motan , MB, ChB Edmonton, AB x Paul Claman , MD Ottawa, ON No. 350, November 2017 DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Figures Figure 1 Ferriman-Gallwey score for hirsutism. Figure 2 Steroidogenesis pathway. Figure 3 Acanthosis nigricans. Abstract Objectives To review the etiology, evaluation, and treatment of hirsutism

2017 Society of Obstetricians and Gynaecologists of Canada

9. Hirsutism

, methyldopa, and sodium valproate). Non-androgen-dependent hair growth (hypertrichosis) can occur with drugs such as minoxidil, ciclosporin, diazoxide, high-dose hydrocortisone, and phenytoin [ ; ]. In menopausal women, a reduction in ovarian estradiol production with relatively stable levels of testosterone production can lead to an increase in hair growth. In some women, increasing concentrations of luteinizing hormone lead to stromal hyperplasia, high testosterone levels, and severe hirsutism (...) (hypertrichosis) can occur with drugs such as minoxidil, ciclosporin, phenytoin, and diazoxide [ ]. No investigations for women with mild hirsutism and no other signs of PCOS or other underlying conditions This recommendation is based on the Endocrine Society clinical practice guideline Evaluation and Treatment of Hirsutism in Premenopausal Women [ ]. Based on very low-quality evidence, the Endocrine Society suggests against investigations in women with isolated mild hirsutism because the likelihood

2014 NICE Clinical Knowledge Summaries

10. A systematic review of commonly used medical treatments for hirsutism in women

A systematic review of commonly used medical treatments for hirsutism in women Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

11. Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials

Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

12. Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials

Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

13. Cyproterone acetate for hirsutism. (Abstract)

Cyproterone acetate for hirsutism. Hirsutism is a distressing and relatively common endocrine problem in women which may prove difficult to manage. Cyproterone acetate, an anti-androgen, is frequently used to treat hirsutism, usually in combination with ethinyl estradiol.The objective of this review was to investigate the effectiveness of cyproterone acetate alone, or in combination with ethinyl estradiol, in reducing hair growth in women with hirsutism secondary to ovarian hyperandrogenism.The (...) controlled trials of cyproterone acetate with or without estrogen versus placebo or other drug therapies for hirsutism were identified.All randomised controlled studies comparing:- cyproterone acetate to placebo- cyproterone acetate with ethinyl estradiol to placebo- cyproterone acetate with ethinyl estradiol to cyproterone acetate alone- cyproterone acetate (with or without estradiol) to other medical therapies for treatment of hirsutism.Eleven studies were identified which fulfilled the inclusion

2003 Cochrane

14. Eflornithine hydrochloride cream for hirsutism - horizon scanning review

Eflornithine hydrochloride cream for hirsutism - horizon scanning review Eflornithine hydrochloride cream for hirsutism - horizon scanning review Eflornithine hydrochloride cream for hirsutism - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Eflornithine hydrochloride cream for hirsutism - horizon (...) scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001 Authors' objectives To summarise the current research evidence on the effectiveness of eflornithine hydrochloride cream for hirsutism. Authors' conclusions Eflornithine cream, a new treatment for hirsutism in woman is in the final stages of development. There is evidence of efficacy although treatment needs to be continued for long-term effectiveness. - Clinical impact: The introduction

2001 Health Technology Assessment (HTA) Database.